The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
How can we address treatment disparities in patients with T-cell lymphoma?
Featured:
Mary Jo LechowiczDuring the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Mary Jo Lechowicz, Winship Cancer institute of Emory University, Atlanta, US. We asked, How can we address treatment disparities in patients with T-cell lymphoma?
How can we address treatment disparities in patients with T-cell lymphoma?
Lechowicz begins by outlining some reasons for these disparities and stresses the importance of international collaboration. She then discusses social determinants for health and current multi center studies, emphasizing that collaboration and communication are key factors.